TAIGEN BIOPHARMACEUTICALS HOLDINGS LIMITED TaiGen Biopharmaceuticals Holdings Limited Stock
Equities
4157
KYG866171005
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.45 TWD | -0.32% |
|
+8.42% | +1.64% |
| Sales 2022 | 36.23M 1.11M | Sales 2023 | 123M 3.77M | Capitalization | 10.91B 334M |
|---|---|---|---|---|---|
| Net income 2022 | -237M -7.27M | Net income 2023 | 137M 4.2M | EV / Sales 2022 | 294 x |
| Net cash position 2022 | 860M 26.37M | Net cash position 2023 | 963M 29.53M | EV / Sales 2023 | 80.8 x |
| P/E ratio 2022 |
-48.5
x | P/E ratio 2023 |
80
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 50% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.32% | ||
| 1 week | +8.42% | ||
| 1 month | +3.69% | ||
| 3 months | +3.69% | ||
| 6 months | +8.80% | ||
| Current year | +1.64% |
1 week
15.20
17.25
1 month
14.1517.25
Current year
14.1517.25
1 year
13.8518.75
3 years
13.0524.90
5 years
8.1938.70
10 years
8.1956.80
| Managers | Title | Age | Since |
|---|---|---|---|
Philip Huang
CEO | Chief Executive Officer | - | 18-12-16 |
Richard Lue
DFI | Director of Finance/CFO | - | 16-03-31 |
Ming-Chu Hsu
BRD | Director/Board Member | - | 01-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shou-Chuan Ho
BRD | Director/Board Member | - | 13-04-28 |
Hong Jen Chang
BRD | Director/Board Member | 68 | 13-03-31 |
Sheng Fu Yu
BRD | Director/Board Member | 79 | 19-06-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 34 M€ | +2.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 15.45 | -0.32% | 3,644,589 |
| 24-04-23 | 15.5 | -0.64% | 3,939,570 |
| 24-04-22 | 15.6 | -5.17% | 13,097,220 |
| 24-04-19 | 16.45 | +4.44% | 26,229,620 |
| 24-04-18 | 15.75 | +9.76% | 10,775,990 |
End-of-day quote Taipei Exchange, April 23, 2024
More quotes
TAIGEN BIOPHARMACEUTICALS HOLDINGS LIMITED is a Taiwan-based company principally engaged in the research and production of pharmaceutical products. The Company's products mainly are new chemical entities (NCEs) in infectious diseases, cancer and diabetes-related complications. Its products include Nemonoxacin, Burlxafor and TG-2349. The Company receives its revenue mainly from the authorization of Nemonoxacin products.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.64% | 342M | |
| -1.51% | 105B | |
| +3.22% | 97.5B | |
| +1.86% | 22.19B | |
| -16.53% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.09% | 14.52B | |
| +5.47% | 14.09B | |
| +28.85% | 10.99B |
- Stock Market
- Equities
- 4157 Stock
